Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 16/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9913766 | 0.91 | SCNN1A (0.58) | SCNN1A | |
| SCHEMBL9913788 | 0.90 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL14268265 | 0.90 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL14210760 | 0.89 | SCNN1A (0.57) | SCNN1A | |
| SCHEMBL9913782 | 0.89 | SCNN1A (0.68) | SCNN1A | |
| SCHEMBL13912813 | 0.89 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL16808735 | 0.89 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL13907673 | 0.89 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL2054438 | 0.89 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL9913772 | 0.89 | SCNN1A (0.64) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931711-B1 | ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-9102633-B2 | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds | PARION SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980898-B2 | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases | PARION SCIENCES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120165342-A1 | Methods of Reducing Risk of Infection from Pathogens | PARION SCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7820678-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7745442-B2 | Methods of reducing risk of infection from pathogens | PARION SCIENCES, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7332496-B2 | Broncholdilator agents; hydration of mucous membranes; respiratory system disorders | PARION SCIENCES, INC. (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20080076782-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20120165342-A1 | Methods of Reducing Risk of Infection from Pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
| US-20150166488-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | SCNN1A 12/4885 |
| US-20150166487-A1 | ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1A | SCNN1A 3/4885 |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | SCNN1A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.